Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
In order to beef up its breakfast offerings, IHOP, one of DineEquity Inc. ( DIN - Snapshot Report ) ’s breakfast oriented brands, recently collaborated with The Quaker Oats Company to develop a new blend of oatmeal. This new breakfast item will be launched in October, featuring three different types of oats in exclusive flavors.
Chicago-based Quaker Oats has been owned by Pepsico Inc. ( PEP - Analyst Report ) since 2001. This the first time Quaker Oats formed an alliance with a Family Dining restaurant chain to create a branded item.
Breakfast has accounted for nearly 60% of the U.S. restaurant industry and remains a key driver of traffic growth in recent years. Thus, both DineEquity and Quaker Oats plan to capitalize on their respective product development talents to create a differentiated line of oatmeal within the burgeoning healthy breakfast category.
We believe that the deal is strategically positive for the parties. Breakfast is considered to be IHOP’s forte as consistent with its brand identity “Everything You Love About Breakfast.” This indicates that both the companies operate almost under the same vertical.
While the deal enables Quaker Oats to leverage IHOP’s industry-leading positioning at breakfast, IHOP will also reap the benefits from Quaker’s more than 100 years of experience in healthy breakfast service. Further, the association paves the way for Quaker Oats to present itself through a different business segment.
In addition to this Oatmeal blends, DineEquity has been striving persistently to give the American breakfast experience at IHOP a new meaning through menu innovation, strategic advertisement, technology and operational improvements.
On the menu front, management is discarding underperforming items and opting for value and innovative breakfast options. It is presently on a test phase with new menu items, some of which will likely hit the market later this year. We believe that the new oatmeal offerings are one of them.
DineEquity currently carries a Zacks #3 Rank, which translates into a short-term Hold rating. We are also maintaining our long-term Neutral recommendation on the stock.
Read the full reports :
Snapshot Report on DIN
Analyst Report on PEP